Boothbay Fund Management
VTGN icon

Boothbay Fund Management’s VistaGen Therapeutics VTGN Stock Holding History

Boothbay Fund Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.4K Hold
134,571
– – ﹤0.01% 2134
2026
Q1 		$76.9K Hold
134,571
– – ﹤0.01% 1893
2025
Q4 		$89.1K Sell
134,571
-62,453
-32% -$226K ﹤0.01% 1751
2025
Q3 		$699K Buy
197,024
+19,166
+11% +$57.3K 0.01% 997
2025
Q2 		$356K Hold
177,858
– – 0.01% 1034
2025
Q1 		$445K Buy
177,858
+155,443
+693% +$440K 0.01% 903
2024
Q4 		$66.1K Buy
+22,415
New +$63.1K ﹤0.01% 1328
2023
Q4 		– Sell
-46,895
Closed -$246K – 2023
2023
Q3 		$246K Buy
+46,895
New +$208K 0.01% 1342
2022
Q2 		– Sell
-2,545
Closed -$95K – 2702
2022
Q1 		$95K Buy
2,545
+1,016
+66% +$44.3K ﹤0.01% 2111
2021
Q4 		$89K Sell
1,529
-402
-21% -$26.2K ﹤0.01% 1728
2021
Q3 		$159K Sell
1,931
-2,316
-55% -$201K ﹤0.01% 1651
2021
Q2 		$401K Sell
4,247
-5,777
-58% -$428K 0.01% 1118
2021
Q1 		$641K Sell
10,024
-5,557
-36% -$371K 0.02% 810
2020
Q4 		$907K Buy
+15,581
New +$398K 0.03% 530

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Boothbay Fund Management's VTGN Position: Q2 2026 in Review

Boothbay Fund Management held its VistaGen Therapeutics (VTGN) position steady in Q2 2026 at 134,571 shares worth $30.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

Boothbay Fund Management first reported a position in VTGN in Q4 2020 and has held it in 14 quarters since. The position peaked at $907K in Q4 2020. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Boothbay Fund Management held 134,571 shares of VistaGen Therapeutics worth $30.4K as of Q2 2026.
  • Boothbay Fund Management left its VistaGen Therapeutics share count unchanged in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2134 holding.
  • Boothbay Fund Management first reported a position in VistaGen Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • Boothbay Fund Management's VistaGen Therapeutics position peaked at $907K in Q4 2020.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.